Compass Therapeutics (NASDAQ:CMPX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.85 EPS.

Separately, Wedbush reissued an outperform rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Wednesday, August 7th.

Compass Therapeutics Trading Up 1.8 %

Shares of Compass Therapeutics stock opened at $1.16 on Monday. The stock has a market capitalization of $159.60 million, a price-to-earnings ratio of -3.22 and a beta of 0.79. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.57. The firm’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.46.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.85 million for the quarter. As a group, equities research analysts predict that Compass Therapeutics will post -0.39 EPS for the current year.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in Compass Therapeutics in the second quarter valued at approximately $41,000. Panagora Asset Management Inc. acquired a new position in Compass Therapeutics in the second quarter valued at approximately $68,000. SG Americas Securities LLC lifted its holdings in Compass Therapeutics by 22.7% in the fourth quarter. SG Americas Securities LLC now owns 47,624 shares of the company’s stock valued at $74,000 after buying an additional 8,817 shares during the period. Bleakley Financial Group LLC acquired a new position in Compass Therapeutics in the first quarter valued at approximately $80,000. Finally, Simplicity Wealth LLC acquired a new position in Compass Therapeutics in the first quarter valued at approximately $80,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.